• Agenus Announces Collaboration and License Agreement with Merck for Novel Checkpoint Antibody-based Cancer Immunotherapies
  • Agenus is eligible to receive ~$100 million in milestone payments as well as royalties on worldwide product sales
 
Agenus - mark

At Agenus, we believe the best path for treating disease is through activating our own body’s natural mechanisms.

That’s why for 20 years, we’ve focused on building technologies and a product pipeline aimed at treating cancer and infectious disease by helping the body’s immune system target diseased cells with precision.

  • August 4, 2014

    Agenus to Present at Conference on Immunomodulatory Therapeutic Antibodies for Cancer
    Read More

     

  • July 24, 2014

    First Vaccine Candidate for Malaria is Accepted for EU Regulatory Review
    Read More

     

  • July 24, 2014

    Agenus Reports Second Quarter 2014 Financial Results
    Read More

     

  • July 1, 2014

    Agenus Brain Cancer Vaccine Shows Extended Survival in Phase 2 Final Data Analysis
    Read More

     

  • June 26, 2014

    Agenus Vaccine Shows Significant Reduction in Viral Burden After HerpV Generated Immune Activation
    Read More

     

  • June 16, 2014

    Agenus Selected for Inclusion in the Russell 3000 Index and Global Index
    Read More